Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]

類似資料

• Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors
  著者:: Wu, Huali, 等
  出版事項: (2015)
• PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse
  著者:: Konishi, Hiroaki, 等
  出版事項: (2012)
• Pharmacokinetic Analysis of Irinotecan Plus Bevacizumab in Patients with Advanced Solid Tumors
  著者:: Denlinger, Crystal S., 等
  出版事項: (2009)
• The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients
  著者:: Ramírez, Jacqueline, 等
  出版事項: (2011)
• Pharmacokinetic characteristics of vincristine sulfate liposomes in patients with advanced solid tumors
  著者:: Yan, Zhao, 等
  出版事項: (2012)